or Try an Advanced Search...

    Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 6.87 4.73% 0.31
    ATNM closed up 4.73 percent on Friday, April 26, 2024, on 50 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 15
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ATNM trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 4.73%
    Oversold Stochastic Weakness 4.73%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.69%
    Inside Day Range Contraction -2.69%
    Wide Bands Range Expansion -2.69%
    Oversold Stochastic Weakness -2.69%
    Wide Bands Range Expansion -1.29%
    Older End-of-Day Signals for ATNM ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 9 hours ago
    Possible Inside Day about 9 hours ago
    Up 5% about 10 hours ago
    Up 3% about 11 hours ago
    60 Minute Opening Range Breakout about 12 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ATNM Chart by TradingView
    Basic chart:

    Profile

    Actinium Pharmaceuticals, Inc. Description

    Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Immunology Natural Sciences Immunotherapy Antibodies Chemical Elements Monoclonal Antibodies Monoclonal Antibody Stem Cell Acute Myeloid Leukemia Platform Technology Transplantation Cancer Center Actinides Hematopoietic Stem Cell Iodine Bismuth Immunotherapy Technology Kettering Cancer Center Memorial Sloan

    Is ATNM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
    Apr 15 Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
    Apr 1 Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant An...
    Mar 26 Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
    Mar 19 Actinium spikes as H.C. Wainwright highlights buyout prospects after Fusion deal
    Mar 15 High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
    Mar 11 Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
    Feb 28 Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade)
    Feb 27 Actinium shares surge on promising data for AML radiotherapy candidate
    Feb 26 Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CI...
    See more ATNM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.8599
    52 Week Low 4.0
    Average Volume 416,818
    200-Day Moving Average 6.23
    50-Day Moving Average 7.78
    20-Day Moving Average 8.07
    10-Day Moving Average 7.16
    Average True Range 0.60
    RSI (14) 40.83
    ADX 24.78
    +DI 17.08
    -DI 26.62
    Chandelier Exit (Long, 3 ATRs) 7.88
    Chandelier Exit (Short, 3 ATRs) 8.27
    Upper Bollinger Bands 10.08
    Lower Bollinger Band 6.06
    Percent B (%b) 0.2
    BandWidth 49.87
    MACD Line -0.32
    MACD Signal Line -0.09
    MACD Histogram -0.2263
    Fundamentals Value
    Market Cap 190.74 Million
    Num Shares 27.8 Million
    EPS -1.93
    Price-to-Earnings (P/E) Ratio -3.56
    Price-to-Sales 266.69
    Price-to-Book 3.48
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.52
    Resistance 3 (R3) 7.47 7.19 7.41
    Resistance 2 (R2) 7.19 7.03 7.22 7.38
    Resistance 1 (R1) 7.03 6.92 7.11 7.09 7.34
    Pivot Point 6.76 6.76 6.80 6.79 6.76
    Support 1 (S1) 6.60 6.59 6.68 6.65 6.40
    Support 2 (S2) 6.32 6.49 6.35 6.36
    Support 3 (S3) 6.16 6.32 6.33
    Support 4 (S4) 6.22